LENSAR, Inc. (LNSR)
NASDAQ: LNSR · Real-Time Price · USD
14.03
+0.12 (0.86%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.
The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room.
LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Nicholas Curtis |
Contact Details
Address: 2800 Discovery Drive Orlando, Florida 32826 United States | |
| Phone | 888 536 7271 |
| Website | lensar.com |
Stock Details
| Ticker Symbol | LNSR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001320350 |
| CUSIP Number | 52634L108 |
| ISIN Number | US52634L1089 |
| Employer ID | 32-0125724 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Nicholas T. Curtis | President, Chief Executive Officer and Director |
| Thomas R. Staab II, CPA | Chief Financial Officer and Secretary |
| Alan B. Connaughton | Chief Operating Officer |
| Kendra W. Wong | Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | SCHEDULE 13G/A | Filing |
| Mar 25, 2025 | SCHEDULE 13D/A | Filing |
| Mar 24, 2025 | DFAN14A | Filing |
| Mar 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 24, 2025 | 8-K | Current Report |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |